EGFR-IN-211

EGFR-IN-211 (Compound T7) exhibits broad-spectrum antiproliferative activity against 9 NCI cancer subtypes after 48 h, with the highest average growth inhibition rate of 136.30% against melanoma, while the IC₅₀ value against colon cancer cell line HT29 is 0.39 μM^[1].
EGFR-IN-211 (48 h) inhibits the migration of HT29 colon cancer cells and reduces the wound healing rate to 33.71% within 48 h^[1].
EGFR-IN-211 (1-3 weeks) reduces the long-term proliferative capacity of HT29 colon cancer cells^[1].
EGFR-IN-211 (0.39 μM; 24 h) disrupts the normal cell cycle progression of HT29 colon cancer cells, leading to cell accumulation at both the G₀/G₁ and G₂/M phases^[1].
EGFR-IN-211 (0.39 μM; 24 h) potently induces apoptosis in HT29 colon cancer cells, primarily elevating the total apoptosis rate to 89.62% via the late apoptosis pathway, with extremely low levels of necrosis^[1].
EGFR-IN-211 (24 h) induces apoptosis in HT29 colon cancer cells, which is evidenced by the enhanced orange-red fluorescence observed via AO/EB staining; this fluorescence indicates that cells are in a state of late apoptosis or secondary necrosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.